X-tosis

X-tosis is a private, preclinical-stage biotech founded in 2018 and based in San Diego, CA. The company is pioneering a novel therapeutic approach targeting mitochondrial dysfunction via modulation of the VDAC1 protein, a mechanism implicated in over 18 neurological and systemic disorders. Its lead program, XTS001, has demonstrated compelling preclinical efficacy in Alzheimer's models, showing improvements in learning, memory, neuronal survival, and reduction of key pathologies. X-tosis is positioning itself as a platform company with a potentially disease-modifying treatment for a high-unmet-need market.

Platform of first-in-class small molecule therapeutics designed to modulate the mitochondrial protein VDAC1, inhibiting its toxic oligomerization to restore mitochondrial function, prevent neuronal apoptosis, and reduce neuroinflammation. Supported by a precision medicine approach using biomarkers for patient selection and monitoring.

X-tosis competes in the crowded neurodegenerative disease space against large pharma and biotechs, but its specific VDAC1 target is first-in-class. Broader competition includes companies targeting mitochondrial function, neuroinflammation, and apoptosis via different mechanisms, many of which are more advanced clinically.